The Process Development Blog

At APC and VLE Therapeutics, we take great pride in our role in advancing the development of therapeutics for rare diseases.

The recent wave of CDMO acquisitions, COVID-19, and global geopolitical uncertainty has underscored the need for pharmaceutical companies to future-proof their manufacturing operations against potential disruptions. In such a climate, Process Portability emerges as a strategic imperative, offering pharmaceutical companies a proactive approach to safeguarding their operations.

This case study highlights the significance of particle size analysis via Dynamic Light Scattering (DLS) in the development of vaccines based on the MVA virus.

APC & VLE Therapeutics, the Irish Multinational group, announce €100M expansion and 300 new jobs to establish ‘The Medicine Accelerator Campus’ in Cherrywood, Dublin

Mark Barrett, CEO shares reflections ahead of some exciting developments to be announced in early 2024.

In this webinar, Guangyang Hou, a Senior Process Development Engineer at APC, explores how model-supported approaches in conjunction with the implementation of Process Analytical Technologies (PAT) and continuous processing, can minimize human intervention whilst drastically reducing development times.

We’re delighted to announce that APC has received Deloitte's 'Ireland's Best Managed Company Award' at a gala in Dublin on September 14, 2023. This award is given based on a company's overall success, including its company culture, management strength, capacity for innovation, strategic initiatives, sustainability, and financial performance.

In this webinar, we will explore the development of a 2nd generation downstream process for a complex biotherapeutic and discuss strategies to significantly reduce the number of unit operations, increase yields, reduce costs, and accelerate time-to-market while meeting CQA specifications.

[PANEL DISCUSSION] CMC data is often fragmented, siloed and lacks context - causing regulatory bottlenecks, manufacturing delays & quality issues.